Kay Tetzlaff


Affiliation: Boehringer Ingelheim


  1. Hall I, Fowler A, Gupta A, Tetzlaff K, Nivens M, Sarno M, et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther. 2015;32:37-44 pubmed publisher
    ..37% (1.57%) for montelukast (p = 0.0050 and p = 0.0657, respectively). These findings suggest that BI 671800 is associated with a small improvement in FEV1 in symptomatic controller-naïve asthma patients, and in patients on ICS. ..
  2. Ichinose M, Kato M, Takizawa A, Sakamoto W, Grönke L, Tetzlaff K, et al. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017;55:121-129 pubmed publisher
    ..No safety concerns for long-term T+O treatment were identified in Japanese patients with COPD. A numerical improvement in lung function was observed with T+O treatment compared to O monotherapy. ..